The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Adverse reactions to first-line antituberculosis drugs
Abstract
INTRODUCTION: Tuberculosis continues to be a major cause of morbidity and mortality worldwide. Currently available drugs are effective for treatment of the disease or latent infection, but may cause serious adverse effects. METHODS: The authors reviewed the literature for side effects of five first-line antituberculous medications (isoniazid, rifampin, pyrazinamide, ethambutol and streptomycin). Incidence of the major side effects were compiled with particular attention to the incidence of isoniazid hepatotoxicity. RESULTS: Hepatotoxicity to isoniazid is a serious problem. Although overall incidence may be decreasing, incidence averaged 9.2 per 1000 patients who were compliant, in multiple studies, with a case fatality rate of 4.7%. The incidence is higher with increasing age. Other serious adverse effects include dermatological, gastrointestinal, hypersensitivity, neurological, haematological and renal reactions. They can lead to drug discontinuation (in up to 10% of patients) or even more serious morbidity or mortality. CONCLUSIONS: Side effects to antituberculosis drugs are common, and include hepatitis, cutaneous reactions, gastrointestinal intolerance, haematological reactions and renal failure. These adverse effects must be recognised early, to reduce associated morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.supplement_3.ats600 · Cited by 1,241
Yee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I., & Menzies, D. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-626oc · Cited by 840
Self-citationControlled chemoprophylaxis trials in tuberculosis. A general review.
Sh, F. (1970) · PubMed · Cited by 721
Iuat (1982) · Bulletin of the World Health Organization · Cited by 515
Isoniazid Liver Injury: Clinical Spectrum, Pathology, and Probable Pathogenesis
MITCHELL, J. R., ZIMMERMAN, H. J., ISHAK, K. G., THORGEIRSSON, U. P., TIMBRELL, J. A., SNODGRASS, W. R., & NELSON, S. D. (1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-84-2-181 · Cited by 505
Toxic Hepatitis with Isoniazid and Rifampin
Steele, M. A., Burk, R. F., & DesPrez, R. M. (1991) · Chest · doi:10.1378/chest.99.2.465 · Cited by 437
Whalen, C. C., Johnson, J. L., Okwera, A., Hom, D. L., Huebner, R., Mugyenyi, P., Mugerwa, R. D., Ellner, J. J., Nsubuga, P., Vjecha, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371201 · Cited by 396
Schaberg, T., Rebhan, K., & Lode, H. (1996) · European Respiratory Journal · doi:10.1183/09031936.96.09102026 · Cited by 379
Isoniazid-Associated Hepatitis in 114 Patients
Black, M., Mitchell, J. R., Zimmerman, H. J., Ishak, K. G., & Epler, G. R. (1975) · Gastroenterology · doi:10.1016/s0016-5085(19)32568-5 · Cited by 370
Nolan, C. M., Goldberg, S. V., & Buskin, S. E. (1999) · JAMA · doi:10.1001/jama.281.11.1014 · Cited by 368
Combs, D. L., O'Brien, R. J., & Geiter, L. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-397 · Cited by 315
Hong Kong Chest Service/Tuberculosis Research Centre, M. M. R. C. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.1.36 · Cited by 304
Mitchell, J. R., Thorgeirsson, U. P., Black, M., Timbrell, J. A., Snodgrass, W. R., Potter, W. Z., Jollow, D. J., & Keiser, H. R. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518170 · Cited by 300
UNGO, J. R., JONES, D., ASHKIN, D., HOLLENDER, E. S., BERNSTEIN, D., ALBANESE, A. P., & PITCHENIK, A. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.6.9711039 · Cited by 292
Halsey, N. A., Coberly, J. S., Desormeaux, J., Losikoff, P., Atkinson, J., Moulton, L. H., Contave, M., Johnson, M., Davis, H., Geiter, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)06532-x · Cited by 270
Ohno, M., Yamaguchi, I., Yamamoto, I., Fukuda, T., Yokota, S., Maekura, R., Ito, M., Yamamoto, Y., Ogura, T., Maeda, K., et al. (2000) · PubMed · Cited by 251
Isoniazid-Associated Hepatitis: Report of an Outbreak 1
Garibaldi, R. A., Drusin, R. E., Ferebee, S. H., & Gregg, M. B. (1972) · American Review of Respiratory Disease · doi:10.1164/arrd.1972.106.3.357 · Cited by 232
Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection
Wong, W.-M., Wu, P.-C., Yuen, M.-F., Cheng, C.-C., Yew, W.-W., Wong, P.-C., Tam, C.-M., Leung, C.-C., & Lai, C.-L. (2000) · Hepatology · doi:10.1002/hep.510310129 · Cited by 231
Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic
LoBue, P. A., & Moser, K. S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200303-390oc · Cited by 224
A controlled trial of community-wide isoniazid prophylaxis in Alaska.
Comstock, G. W., Ferebee, S. H., & Hammes, L. M. (1967) · PubMed · doi:10.1164/arrd.1967.95.6.935 · Cited by 211
Twice weekly tuberculosis preventive therapy in HIV infection in Zambia
Mwinga, A., Hosp, M., Godfrey-Faussett, P., Quigley, M., Mwaba, P., Mugala, B. N., Nyirenda, O., Luo, N., Pobee, J., Elliott, A. M., et al. (1998) · AIDS · doi:10.1097/00002030-199818000-00014 · Cited by 211
Potentially Serious Side Effects of High-dose Twice-weekly Rifampicin
Poole, G., Stradling, P., & Worlledge, S. (1971) · BMJ · doi:10.1136/bmj.3.5770.343 · Cited by 209
Jasmer, R. M., Saukkonen, J. J., Blumberg, H. M., Daley, C. L., Bernardo, J., Vittinghoff, E., King, M. D., Kawamura, L. M., Hopewell, P. C., & for the Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-8-200210150-00007 · Cited by 201
Isoniazid-associated Hepatitis Deaths: A Review of Available Information
Snider, D. E., & Caras, G. J. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.2_pt_1.494 · Cited by 199
Ferebee, S. H., & MOUNT, F. W. (1962) · PubMed · doi:10.1164/arrd.1962.85.4.490 · Cited by 187
Adverse Effects of Antituberculosis Drugs
Girling, D. J. (1982) · Drugs · doi:10.2165/00003495-198223010-00003 · Cited by 182
Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A
Desta, Z., Soukhova, N. V., & Flockhart, D. A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.382-392.2001 · Cited by 180
MADDREY, W. C., & BOITNOTT, J. K. (1973) · Annals of Internal Medicine · doi:10.7326/0003-4819-79-1-1 · Cited by 175
Gordin, F. M., Matts, J. P., Miller, C., Brown, L. S., Hafner, R., John, S. L., Klein, M., Vaughn, A., Besch, C. L., Perez, G., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370505 · Cited by 166
Hong Kong Chest Service/British Medical Research Council (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/143.4_pt_1.700 · Cited by 163
Frequency and type of reactions to antituberculosis drugs: Observations in routine treatment
Ormerod, L. P., & Horsfield, N. (1996) · Tubercle and Lung Disease · doi:10.1016/s0962-8479(96)90073-8 · Cited by 158
Serum Transaminase Elevations and Other Hepatic Abnormalities in Patients Receiving Isoniazid
Scharer, L. L. M. D., & SMITH, J. P. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-6-1113 · Cited by 155
Parthasarathy, R., Sarma, G. R., Janardhanam, B., Ramachandran, P., Santha, T., Sivasubramanian, S., Somasundaram, P. R., & Tripathy, S. P. (1986) · Tubercle · doi:10.1016/0041-3879(86)90003-6 · Cited by 150
Psychiatric Morbidity in Psoriasis and Vitiligo: A Comparative Study
Sharma, N., Koranne, R. V., & Singh, R. K. (2001) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2001.tb00003.x · Cited by 149
Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults
Hawken, M. P., Meme, H., Elliott, L. C., et al. (1997) · AIDS · doi:10.1097/00002030-199707000-00006 · Cited by 141
Rifampicin-associated acute renal failure: Pathophysiologic, immunologic, and clinical features
De Vriese, A., Robbrecht, D., Vanholder, R., Vogelaers, D., & Lameire, N. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v31.pm9428460 · Cited by 135
Adverse reactions to rifampicin in antituberculosis regimens
Girling, D. J. (1977) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/3.2.115 · Cited by 135
Pyrazinamide and Rifampin vs Isoniazid for the Treatment of Latent Tuberculosis
McNeill, L., Allen, M. G., Estrada, C. A., & Cook, P. (2003) · CHEST Journal · doi:10.1378/chest.123.1.102 · Cited by 135
Papastavros, T., Dolovich, L. R., Holbrook, A. M., et al. (2002) · PubMed · Cited by 126
Ethambutol Ocular Toxicity in Treatment Regimens for Mycobacterium avium Complex Lung Disease
Griffith, D. E., Brown‐Elliott, B. A., Shepherd, S., McLarty, J. W., Griffith, L., & Wallace, R. J. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200407-863oc · Cited by 126
Hepatotoxicity of Rifampin-Pyrazinamide and Isoniazid Preventive Therapy and Tuberculosis Treatment
van Hest, R., Baars, H., Kik, S. V., van Gerven, P., Trompenaars, M. E., Kalisvaart, N. A., Keizer, S. T., Borgdorff, M. W., Mensen, M., & Cobelens, F. G. J. (2004) · Clinical Infectious Diseases · doi:10.1086/422645 · Cited by 125
The management of anti-tuberculosis drug-induced hepatotoxicity.
Tahaoğlu, K., Ataç, G., Sevim, T., Tärün, T., Yazıcıoğlu, Ö. M., Horzum, G., Gemci, I., Ongel, A., Kapaklı, N., & Aksoy, E. (2001) · PubMed · Cited by 123
Rb, B. (1979) · JAMA · doi:10.1001/jama.241.12.1239 · Cited by 123
Sarma, G. R., Immanuel, C., Kailasam, S., Narayana, A. S. L., & Venkatesan, P. (1986) · PubMed · doi:10.1164/arrd.1986.133.6.1072 · Cited by 116
Rifampicin-induced acute renal failure: a series of 60 patients
Covic, A. C., Goldsmith, D. J. A., Segall, L., Stoicescu, C. I., Lungu, S., Volovăţ, C., & Covic, M. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.4.924 · Cited by 116
Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore.
Teleman, M. D., Chee, C. B. E., Earnest, A., & Wang, Y. T. (2002) · PubMed · Cited by 111
Should Women Taking Antituberculosis Drugs Breast-feed?
Snider, D. E., & Powell, K. R. (1984) · Archives of Internal Medicine · doi:10.1001/archinte.1984.00350150199040 · Cited by 111
Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.
Grönhagen-Riska, C., Hellström, P. E., & Fröseth, B. (1978) · PubMed · doi:10.1164/arrd.1978.118.3.461 · Cited by 109
Rose, D. N. (1986) · JAMA · doi:10.1001/jama.1986.03380190079029 · Cited by 105
Benito, N., Sued, O. G., Moreno, A. N., Horcajada, J. P., lez, J. G., Navasa, M., & Rimola, A. (2002) · Transplantation · doi:10.1097/00007890-200211270-00006 · Cited by 98
Severe Acetaminophen Toxicity in a Patient Receiving Isoniazid
Murphy, R., Swartz, R. H., & Watkins, P. B. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-10-799 · Cited by 98
Acetylation Rates and Monthly Liver Function Tests during One Year of Isoniazid Preventive Therapy
Mitchell, J. R., Long, M. W., Thorgeirsson, U. P., & Jollow, D. J. (1975) · Chest · doi:10.1378/chest.68.2.181 · Cited by 95
A controlled trial of isoniazid prophylaxis in mental institutions
Ferebee, S. H., MOUNT, F. W., Murray, F. J., & Livesay, V. T. (1964) · Nursing Research · doi:10.1097/00006199-196401320-00046 · Cited by 91
Durand, F., Bernuau, J., Pessayre, D., Samuel, D., Bélaïche, J., Degott, C., Bismuth, H., Belghiti, J., Erlinger, S., RUEFF, B., et al. (1995) · Hepatology · doi:10.1002/hep.1840210407 · Cited by 88
Melamud, A., Kosmorsky, G. S., & Lee, M. S. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.11.1409 · Cited by 87
Hepatotoxicity from Isoniazid and Rifampin Among Children Treated for Tuberculosis
O'Brien, R. J., Long, M. W., Cross, F. S., Lyle, M. A., & Snider, D. E. (1983) · PEDIATRICS · doi:10.1542/peds.72.4.491 · Cited by 86
Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.
Salpeter, S. R. (1993) · PubMed Central · Cited by 84
Gurumurthy, P., Krishnamurthy, M. S., Nazareth, O., Parthasarathy, R., Sarma, G. R., Somasundaram, P. R., Tripathy, S. P., & Ellard, G. A. (1984) · PubMed · doi:10.1164/arrd.1984.129.1.58 · Cited by 81
Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis
Stout, J. E., Engemann, J. J., Cheng, A. C., Fortenberry, E. R., & HAMILTON, C. D. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200209-998oc · Cited by 80
Lee, A. M., Mennone, J. Z., Jones, R. C., et al. (2002) · PubMed · Cited by 77
Risk factors for antituberculous chemotherapy‐induced hepatotoxicity in Japanese pediatric patients
Ohkawa, K., Hashiguchi, M., Ohno, K., Chikako, K., Takahashi, S., Kondo, S., Echizen, H., & Ogata, H. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126175 · Cited by 74
Lee, B., Koh, W., Choi, M. S., Suh, G. Y., Chung, M. P., Kim, H., & Kwon, O. J. (2005) · CHEST Journal · doi:10.1016/s0012-3692(15)34481-0 · Cited by 72
Smear- and Culture-negative Pulmonary Tuberculosis: Four-month Short-course Chemotherapy
Dutt, A. K., Moers, D., & Stead, W. W. (1989) · American Review of Respiratory Disease · doi:10.1164/ajrccm/139.4.867 · Cited by 71
Alao, A. O., & Yolles, J. C. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17377 · Cited by 66
Isoniazid Hepatotoxicity among Drug Users: The Role of Hepatitis C
Fernández‐Villar, A., SOPEÑA, B., Vázquez, R., Ulloa, F., Fluiters, E., Mosteiro, M., Martínez-Vázquez, C., & Piñeiro, L. (2003) · Clinical Infectious Diseases · doi:10.1086/345906 · Cited by 66
A correlation between changes in GABA metabolism and isonicotinic acid hydrazide-induced seizures
Wood, J. D., & Peesker, S. J. (1972) · Brain Research · doi:10.1016/0006-8993(72)90477-5 · Cited by 65
Service, H. K. C. (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/143.2.262 · Cited by 63
Sadaphal, P., Astemborski, J. A., Graham, N. M. H., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/323896 · Cited by 61
Aging and Hepatotoxicity of Isoniazid and Rifampin in Pulmonary Tuberculosis
den Brande, P. V., Steenbergen, W. V., Vervoort, G., & DEMEDTS, M. G. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.5.7582317 · Cited by 56
Isoniazid and Reaction to Cheese
SMITH, C. K., & DURACK, D. T. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-88-4-520 · Cited by 52
Lou, H., Shullo, M. A., & McKaveney, T. P. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.9.701.34065 · Cited by 51
Adverse Events and Treatment Completion for Latent Tuberculosis in Jail Inmates and Homeless Persons
Lobato, M. N., Reves, R. R., Jasmer, R. M., Grabau, J. C., BOCK, N. N., & Shang, N. (2005) · CHEST Journal · doi:10.1016/s0012-3692(15)34480-9 · Cited by 51
Singapore Tuberculosis Service/British Medical Research Council (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/143.4_pt_1.707 · Cited by 50
Hepatitis cases in isoniazid treated groups and in a control group.
Riska, N. (1976) · PubMed · Cited by 47
Gj, V. (1968) · PubMed · Cited by 46
Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland.
HORWITZ, O., Pg, P., & Wilbek, E. (1966) · PubMed · Cited by 46
Leung, C. C., Law, W. S., Chang, K. C., Tam, C. M., Yew, W. W., Chan, C. K., & Wong, M. (2003) · CHEST Journal · doi:10.1378/chest.124.6.2112 · Cited by 43
Isoniazid induced pellagra despite pyridoxine supplementation
Darvay, Basarab, McGregor, & Russell-Jones (1999) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.1999.00444.x · Cited by 42
Tsankov, N., & Angelova, I. (2003) · Clinics in Dermatology · doi:10.1016/s0738-081x(02)00328-0 · Cited by 35
Pyridoxine-Responsive Anemia Conditioned by Isonicotinic Acid Hydrazide
McCurdy, P. R., & Donohoe, R. F. (1966) · Blood · doi:10.1182/blood.v27.3.352.352 · Cited by 35
Lee, B. (2005) · CHEST Journal · doi:10.1378/chest.127.4.1304 · Cited by 35
Side-effects of antituberculosis drug treatment in patients with chronic renal failure
Quantrill, S. J., Woodhead, M. A., Bell, C. E., Hardy, C., Hutchison, A. J., & Gokal, R. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00298002 · Cited by 34
Isoniazid-lnduced Convulsions: Part I—Clinical
Coyer, J. R., & NICHOLSON, D. P. (1976) · Southern Medical Journal · doi:10.1097/00007611-197603000-00014 · Cited by 32
Rapidly Progressive Glomerulonephritis due to Rifampicin Therapy
Yoshioka, K., Satake, N., Kasamatsu, Y., Nakamura, Y., & Shikata, N. (2001) · The Nephron journals/Nephron journals · doi:10.1159/000046326 · Cited by 31
Cholestatic jaundice caused by ethambutol.
Gulliford, M. C., Mackay, A. D., & Prowse, K. (1986) · BMJ · doi:10.1136/bmj.292.6524.866 · Cited by 30
Rifampin-Induced Hypothyroidism in Patients with Hashimoto's Thyroiditis
Takasu, N., Takara, M., & Komiya, I. (2005) · New England Journal of Medicine · doi:10.1056/nejm200502033520524 · Cited by 27 · cited 1×
“RIF has been reported to induce hypothyroidism necessitating thyroxin replacement, which could be discontinued after rifampin was stopped [168].”
BackgroundPyrazinamide-Induced Granulomatous Hepatitis
Knobel, B., Buyanowsky, G., Dan, M., & Zaidel, L. (1997) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199706000-00019 · Cited by 27
Ogata, H., Kubo, M., Tamaki, K., Hirakata, H., Okuda, S., & Fujishima, M. (1998) · The Nephron journals/Nephron journals · doi:10.1159/000044942 · Cited by 27
Isoniazid and Reaction to Cheese
Lejonc, J. L., Gusmini, D., & Brochard, P. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-793_1 · Cited by 26
Lobato, M. N. (2005) · CHEST Journal · doi:10.1378/chest.127.4.1296 · Cited by 26
Extensive Striae Distensae as a Result of Topical Corticosteroid Therapy in Psoriasis Vulgaris
Rogalski, C., & Rogalski, C. (2003) · Acta Dermato Venereologica · doi:10.1080/00015550310002747 · Cited by 22
Paradoxical Pleural Response to Antituberculous Chemotherapy and Isoniazid-Induced Lupus
Hiraoka, K., Nagata, N., Kawajiri, T., Suzuki, K., Kurokawa, S., Kido, M., & Sakamoto, N. (1998) · Respiration · doi:10.1159/000029251 · Cited by 21
Romano, A. G., Viola, M., Fonso, M. D., Perrone, M. R., Gaeta, F., & Andriolo, M. (2002) · Allergy · doi:10.1034/j.1398-9995.2002.23836_9.x · Cited by 21
Felten, M. K., & Merwe, C. A. V. D. (1989) · American Review of Respiratory Disease · doi:10.1164/ajrccm/140.4.1001 · Cited by 20
Minimal change nephrotic syndrome associated with rifampicin treatment
Kohno, K., Mizuta, Y., Yoshida, T., Watanabe, H., Nishida, H., Fukami, K., Iida, S., Haramaki, R., Wada, Y., Tamai, O., et al. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.7.1056 · Cited by 19
Kobayashi, K., HARUTA, T., Maeda, H., Kubota, M., & Nishio, T. (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200211000-00029 · Cited by 13
Cited by
Antituberculosis drugs: Ten years of research
Janin, Y. L. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.01.030 · Cited by 485
Devarbhavi, H., Dierkhising, R., Kremers, W. K., Sandeep, M. S., Karanth, D., & Adarsh, C. K. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.287 · Cited by 195
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
McDonagh, E. M., Boukouvala, S., Aklillu, E., Hein, D. W., Altman, R. B., & Klein, T. E. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000062 · Cited by 146
Devarbhavi, H., Singh, R., Patil, M., Sheth, K., Adarsh, C. K., & Balaraju, G. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07279.x · Cited by 86
Metadata
- Authors
- Forget, E. J., & Menzies, D.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2006-02-27
- Volume
- 5
- Issue
- 2
- Pages
- 231-249
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2012393743
- Cited by
- 315
- References
- 99
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.